Patient characteristics and outcome
| . | Total . | GO+ . | GO− . | P . |
|---|---|---|---|---|
| Patients, N | 145 | 48 | 97 | |
| Age (years), median (range) | 43 (16-76) | 46 (20-76) | 42 (16-74) | .15 |
| Gender (male/female), N | 77/68 | 26/22 | 51/46 | .99 |
| CBFA/CBFB, N | 59/86 | 25/23 | 34/63 | .07 |
| CR1 duration (months), median (range) | 12.1 (2.1-93.6) | 11.1 (2.1-93.6) | 12.7 (2.6-55.2) | .04 |
| Primary trial | <.001 | |||
| ALFA-9801, N (%) | 21 (14) | 8 (17) | 13 (13) | |
| ALFA-9802, N (%) | 20 (14) | 1 (2) | 19 (20) | |
| LAM-2001, N (%) | 47 (32) | 7 (14) | 40 (41) | |
| CBF-2006, N (%) | 57 (39) | 32 (67) | 25 (26) | |
| CR2, N (%) | 127 (88) | 42 (88) | 85 (88) | .99 |
| Allograft, N (%) | 78 (54) | 28 (58) | 50 (52) | .55 |
| . | Total . | GO+ . | GO− . | P . |
|---|---|---|---|---|
| Patients, N | 145 | 48 | 97 | |
| Age (years), median (range) | 43 (16-76) | 46 (20-76) | 42 (16-74) | .15 |
| Gender (male/female), N | 77/68 | 26/22 | 51/46 | .99 |
| CBFA/CBFB, N | 59/86 | 25/23 | 34/63 | .07 |
| CR1 duration (months), median (range) | 12.1 (2.1-93.6) | 11.1 (2.1-93.6) | 12.7 (2.6-55.2) | .04 |
| Primary trial | <.001 | |||
| ALFA-9801, N (%) | 21 (14) | 8 (17) | 13 (13) | |
| ALFA-9802, N (%) | 20 (14) | 1 (2) | 19 (20) | |
| LAM-2001, N (%) | 47 (32) | 7 (14) | 40 (41) | |
| CBF-2006, N (%) | 57 (39) | 32 (67) | 25 (26) | |
| CR2, N (%) | 127 (88) | 42 (88) | 85 (88) | .99 |
| Allograft, N (%) | 78 (54) | 28 (58) | 50 (52) | .55 |